October 27, 2021 -- DNA Script has raised $165 million in a series C financing round led by Coatue Management and Catalio Capital Management.
DNA Script said the funds will help the company support expansion and commercialization of its Syntax benchtop DNA printing platform and broaden the portfolio of products powered by enzymatic DNA synthesis technology. The firm has raised a total of $280 million since its inception.
The oversubscribed funding round included participation by new investors Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital, and Moore Strategic Ventures. Existing investors Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners, and Alexandria Venture Investments were also involved in the funding round, according to DNA Script.
Representatives from Coatue and Catalio have joined the company's board as observers.